Bristol Myers Squibb, AstraZeneca, Eli Lilly and other drug companies have invested some $10 billion on promising cancer technology behind Novartis’ Pluvicto.
Recent Posts
- Dow dips more than 100 points, falling for the first time in 5 sessions: Live updates
- More than 90% of 401(k) plans now offer Roth contributions – but only 21% of workers take advantage
- 10-year Treasury yield rises above 4.6% ahead of jobless claims
- Dow futures fall more than 100 points the day after Christmas: Live updates
- Larry Ellison wraps up banner year as Oracle’s stock rallies most since dot-com boom